<!doctype html><html class=no-js lang=en><head><meta charset=UTF-8><meta name=viewport content="width=device-width,initial-scale=1"><title>ç§‘ç ”æ—¥æŠ¥ 2025-11-16 - ç”Ÿä¿¡æ™®æ‹‰æ–¯</title>
<script>(function(e,t){e[t]=e[t].replace("no-js","js")})(document.documentElement,"className")</script><meta name=description content><meta property="og:url" content="https://ixxmu.github.io/posts/dailyreports/2025-11-16/"><meta property="og:site_name" content="ç”Ÿä¿¡æ™®æ‹‰æ–¯"><meta property="og:title" content="ç§‘ç ”æ—¥æŠ¥ 2025-11-16"><meta property="og:description" content="ğŸ“… Daily Report - 2025-11-16 ä»Šæ—¥ç­›é€‰å‡º 85 æ¡å†…å®¹ï¼Œæ¥è‡ª 3 ä¸ªæ¥æº"><meta property="og:locale" content="zh_cn"><meta property="og:type" content="article"><meta property="article:section" content="posts"><meta property="article:published_time" content="2025-11-16T00:00:00+00:00"><meta property="article:modified_time" content="2025-11-16T00:00:00+00:00"><meta property="article:tag" content="Research"><meta property="article:tag" content="Daily"><meta property="article:tag" content="Week462025"><meta itemprop=name content="ç§‘ç ”æ—¥æŠ¥ 2025-11-16"><meta itemprop=description content="ğŸ“… Daily Report - 2025-11-16 ä»Šæ—¥ç­›é€‰å‡º 85 æ¡å†…å®¹ï¼Œæ¥è‡ª 3 ä¸ªæ¥æº"><meta itemprop=datePublished content="2025-11-16T00:00:00+00:00"><meta itemprop=dateModified content="2025-11-16T00:00:00+00:00"><meta itemprop=wordCount content="2329"><meta itemprop=keywords content="Research,Daily,Week462025"><meta name=twitter:card content="summary"><meta name=twitter:title content="ç§‘ç ”æ—¥æŠ¥ 2025-11-16"><meta name=twitter:description content="ğŸ“… Daily Report - 2025-11-16 ä»Šæ—¥ç­›é€‰å‡º 85 æ¡å†…å®¹ï¼Œæ¥è‡ª 3 ä¸ªæ¥æº"><link rel=preconnect href=https://fonts.gstatic.com crossorigin><link rel=dns-prefetch href=//fonts.googleapis.com><link rel=dns-prefetch href=//fonts.gstatic.com><link rel=stylesheet href="https://fonts.googleapis.com/css?family=Open+Sans:400,400i,700"><link rel=stylesheet href=../../../css/style.css><link rel=stylesheet href=../../../css/custom.css><link rel="shortcut icon" href=../../../favicon.ico></head><body class=body><div class="container container--outer"><header class=header><div class="container header__container"><div class=logo><a class=logo__link href=../../../ title=ç”Ÿä¿¡æ™®æ‹‰æ–¯ rel=home><div class="logo__item logo__text"><div class=logo__title>ç”Ÿä¿¡æ™®æ‹‰æ–¯</div><div class=logo__tagline>è¿‘åå¹´æœ€å€¼å¾—ä¸Šæ‰‹çš„ç”Ÿç‰©åŒ»å­¦ç”Ÿä¿¡ä»£ç </div></div></a></div><nav class=menu><button class=menu__btn aria-haspopup=true aria-expanded=false tabindex=0>
<span class=menu__btn-title tabindex=-1>Menu</span></button><ul class=menu__list><li class=menu__item><a class=menu__link href=../../../posts/><span class=menu__text>æ–‡ç« </span></a></li><li class=menu__item><a class=menu__link href=../../../tags/><span class=menu__text>æ ‡ç­¾</span></a></li><li class=menu__item><a class=menu__link href=../../../about/><span class=menu__text>å…³äº</span></a></li></ul></nav></div></header><div class="wrapper flex"><div class=primary><main class=main role=main><article class=post><header class=post__header><meta name=referrer content="never"><h1 class=post__title>ç§‘ç ”æ—¥æŠ¥ 2025-11-16</h1><div class="post__meta meta"><div class="meta__item-datetime meta__item"><svg class="meta__icon icon icon-time" width="16" height="14" viewBox="0 0 30 28"><path d="M15 0a14 14 0 110 28 1 1 0 010-28m0 3a3 3 0 100 22 3 3 0 000-22m1 4h-2v8.4l6.8 4.4L22 18l-6-3.8z"/></svg><time class=meta__text datetime=2025-11-16T00:00:00Z>2025-11-16</time></div><div class="meta__item-categories meta__item"><svg class="meta__icon icon icon-category" width="16" height="16" viewBox="0 0 16 16"><path d="m7 2 1 2h8v11H0V2z"/></svg><span class=meta__text><a class=meta__link href=../../../categories/dailyreport/ rel=category>DailyReport</a></span></div><div class="meta__item-author meta__item"><svg class="meta__icon icon icon-author" width="16" height="16" viewBox="0 0 16 16"><path d="M8 1c2 0 3.5 2 3.5 4.5S10 9 10 9c3 1 4 2 4 6H2c0-4 1-5 4-6 0 0-1.5-1-1.5-3.5S6 1 8 1"/></svg><span class=meta__text>Bloger</span></div></div></header><div class="post__toc toc"><div class=toc__title>Page content</div><div class=toc__menu><nav id=TableOfContents><ul><li><a href=#-ä»Šæ—¥aiæ™ºèƒ½æ€»ç»“>ğŸ¤– ä»Šæ—¥AIæ™ºèƒ½æ€»ç»“</a><ul><li><a href=#-å…¬ä¼—å·>ğŸ“° å…¬ä¼—å·</a></li><li><a href=#-æ•°æ®å‰æ²¿>ğŸ§¬ æ•°æ®å‰æ²¿</a></li><li><a href=#-åšå®¢æ›´æ–°>ğŸ§ª åšå®¢æ›´æ–°</a></li></ul></li><li><a href=#-åˆ†ç±»æµè§ˆ>ğŸ“š åˆ†ç±»æµè§ˆ</a><ul><li></li></ul></li><li><a href=#-å…³é”®è¯ç»Ÿè®¡>ğŸ“Š å…³é”®è¯ç»Ÿè®¡</a></li><li><a href=#-æ›´å¤šå†…å®¹>ğŸ“ æ›´å¤šå†…å®¹</a></li></ul></nav></div></div><div class="content post__content clearfix"><h1 id=-daily-report---2025-11-16>ğŸ“… Daily Report - 2025-11-16</h1><blockquote><p>ä»Šæ—¥ç­›é€‰å‡º <strong>85</strong> æ¡å†…å®¹ï¼Œæ¥è‡ª <strong>3</strong> ä¸ªæ¥æº</p></blockquote><div class=powered-by-top>Powered by <a href=https://kyplus.de>ç§‘ç ”æ™®æ‹‰æ–¯</a> & <a href=https://claude.ai>Claude</a></div><hr><h2 id=-ä»Šæ—¥aiæ™ºèƒ½æ€»ç»“>ğŸ¤– ä»Šæ—¥AIæ™ºèƒ½æ€»ç»“</h2><h3 id=-å…¬ä¼—å·>ğŸ“° å…¬ä¼—å·</h3><blockquote><p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š
å—æ–¹åŒ»ç§‘å¤§å­¦å—æ–¹åŒ»é™¢å‘ç°MCUB-PRKNç›¸äº’ä½œç”¨æ˜¯å…‹æœè‚¿ç˜¤å…ç–«è€è¯æ€§çš„æ–°å‹é©±åŠ¨å› ç´ ï¼›è¥¿æ¹–å¤§å­¦å›¢é˜Ÿåœ¨ã€Šç§‘å­¦ã€‹å‘æ–‡ï¼Œæ‰¾åˆ°æ ‘çªçŠ¶ç»†èƒå‘ˆé€’æŠ—åŸã€æ¿€æ´»Tç»†èƒçš„å…³é”®åˆ†å­ã€‚</p></blockquote><p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š</p><ul><li><strong>è‚¿ç˜¤å…ç–«å¾®ç¯å¢ƒè°ƒæ§</strong>ï¼šèšç„¦å•ç»†èƒã€ç©ºè½¬åˆ†æMMP1ã€ECMé‡å¡‘ã€æŠ—åŸå‘ˆé€’ç»†èƒï¼ˆæ ‘çªçŠ¶ç»†èƒã€ç™Œç—‡ç›¸å…³æˆçº¤ç»´ç»†èƒï¼‰åœ¨è‚¿ç˜¤å…ç–«ä¸­çš„ä½œç”¨åŠé¢„æµ‹ç–—æ•ˆã€‚</li><li><strong>è‚¿ç˜¤è½¬ç§»ä¸è€è¯æœºåˆ¶</strong>ï¼šè§£æå¾ªç¯è‚¿ç˜¤ç»†èƒï¼ˆCTCsï¼‰è½¬ç§»è·¯å¾„ï¼Œæ­ç¤ºå…ç–«é€ƒé€¸æ–°å‹é©±åŠ¨å› ç´ åŠTGF-Î²æŠ‘åˆ¶è‚¿ç˜¤ç”Ÿé•¿çš„åˆ†å­æœºåˆ¶ã€‚</li><li><strong>è‚ è„‘è½´ä¸ä»£è°¢é€šè·¯</strong>ï¼šç ”ç©¶è‚ é“èŒç¾¤-ä»£è°¢ç‰©-ç‚ç—‡é€šè·¯ï¼Œä»¥åŠæ°¨åŸºé…¸ä»£è°¢åœ¨ç–¾ç—…ä¸­çš„ä½œç”¨ã€‚</li></ul><p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š</p><ul><li><strong>å¤šç»„å­¦æ•´åˆåˆ†æ</strong>ï¼šç»“åˆå•ç»†èƒã€ç©ºè½¬ã€åŸºå› ç»„å­¦ï¼ˆGWASï¼‰ç­‰æŠ€æœ¯ï¼Œå®ç°è·¨ç»„ç»‡ã€è·¨ç‰©ç§æ•°æ®æ•´åˆï¼ˆSATURNï¼‰ï¼Œå¹¶å¼€å‘Phiclustã€Augurã€BiomarkerMLç­‰åˆ†æå·¥å…·ã€‚</li><li><strong>å¹²æ¹¿ç»“åˆéªŒè¯</strong>ï¼šé€šè¿‡å…³é”®åŸºå› åŠŸèƒ½éªŒè¯ï¼ˆå¦‚MMP1ã€ECMé‡å¡‘ç›¸å…³æˆçº¤ç»´ç»†èƒã€Ms4a7ã€AOAHç­‰ï¼‰å’Œå®éªŒæ”¹é€ ï¼ˆè›‹ç™½å·¥ç¨‹åŒ–ã€åŸºå› ç¼–è¾‘ï¼‰æ¥æ·±åŒ–ç ”ç©¶ã€‚</li></ul><h3 id=-æ•°æ®å‰æ²¿>ğŸ§¬ æ•°æ®å‰æ²¿</h3><blockquote><p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š
å•ç»†èƒRNAæµ‹åºæ­ç¤ºäº†å®«é¢ˆç™Œè‚¿ç˜¤å¾®ç¯å¢ƒä¸­å…ç–«ç»†èƒçš„è¯¦ç»†æ„æˆä¸åŠŸèƒ½ç‰¹å¾ï¼Œå¹¶å‘ç°äº†æ–°çš„é—´å……è´¨ç»†èƒäºšç¾¤ã€‚</p></blockquote><p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š</p><ul><li>ç™Œç—‡å…ç–«å¾®ç¯å¢ƒåˆ†æï¼šæ·±å…¥è§£æå®«é¢ˆç™Œã€ç»“ç›´è‚ ç™Œã€è‚ç»†èƒç™Œç­‰å¤šç§ç™Œç—‡çš„å…ç–«ç»†èƒç»„æˆã€åŠŸèƒ½åŠå¯¹æ²»ç–—çš„å“åº”ã€‚</li><li>åŸºå› è½¬å½•ä¸è¡¨è§‚é—ä¼ è°ƒæ§ï¼šç ”ç©¶BRG1ç¼ºå¤±ã€DNAç”²åŸºåŒ–å¼‚å¸¸ã€SOX2ç£·é…¸åŒ–ã€KMT2Dåœ¨è‚ºç™Œã€ATRTã€å°è„‘é¢—ç²’ç»†èƒåˆ†åŒ–ä¸­çš„ä½œç”¨ã€‚</li><li>ç–¾ç—…æ¨¡å‹ä¸ä¿¡å·é€šè·¯ï¼šæ„å»ºå¤šå™¨å®˜ç±»å™¨å®˜å¹³å°æ¨¡æ‹Ÿå¿ƒè„æŸä¼¤ï¼Œæ¢ç©¶COPDã€é«˜æµ·æ‹”è®¤çŸ¥éšœç¢ã€EBV+èƒƒç™Œçš„è½¬å½•ç»„ç‰¹å¾åŠPI3K/AKTã€æ°§åŒ–ç£·é…¸åŒ–ç­‰ä¿¡å·é€šè·¯ã€‚</li></ul><p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š</p><ul><li>å¤šç»„å­¦è”åˆåˆ†æï¼šç»“åˆå•ç»†èƒRNAæµ‹åºï¼ˆscRNA-seqï¼‰ã€ç©ºé—´è½¬å½•ç»„å­¦ã€ChIP-Seqã€ATAC-Seqç­‰æŠ€æœ¯ï¼Œå®ç°å¯¹ç»†èƒå¼‚è´¨æ€§ã€åŸºå› è°ƒæ§åŠç©ºé—´ç»„ç»‡çš„å¤šç»´åº¦è§£æã€‚</li><li>äººå·¥æ™ºèƒ½è¯Šæ–­æ¨¡å‹ï¼šåˆ©ç”¨è¡€æ¸…å¤–æ³Œä½“miRNAæ„å»ºAIæ¨¡å‹ï¼Œå®ç°è‚ç»†èƒç™Œçš„é«˜ç²¾åº¦æ£€æµ‹ã€‚</li></ul><h3 id=-åšå®¢æ›´æ–°>ğŸ§ª åšå®¢æ›´æ–°</h3><blockquote><p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š
New England Biolabs (NEB) æ¨å‡ºæ–°å‹ NEBNextÂ® Flu A Integrated Indexing Primer Moduleï¼Œ<strong>é¦–æ¬¡</strong>å®ç°é›†æˆåŒ–æ–‡åº“åˆ¶å¤‡ï¼Œæ˜¾è‘—åŠ é€Ÿé«˜é€šé‡æµæ„Ÿ A ç—…æ¯’æµ‹åºã€‚</p></blockquote><p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š</p><ul><li>æµæ„Ÿ A ç—…æ¯’ RNA æµ‹åº</li><li>å…¨çƒæ€§æµæ„Ÿç›‘æµ‹</li></ul><p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š</p><ul><li>é›†æˆåŒ–æ–‡åº“åˆ¶å¤‡å·¥ä½œæµç¨‹</li><li>é«˜é€šé‡æµ‹åºæ•ˆç‡æå‡</li></ul><hr><h2 id=-åˆ†ç±»æµè§ˆ>ğŸ“š åˆ†ç±»æµè§ˆ</h2><details><summary style="text-align:right;direction:rtl;padding:10px 15px;background:linear-gradient(135deg,#f8f9fa 0%,#e9ecef 100%);border-right:4px solid #667eea;font-weight:600;cursor:pointer;margin:15px 0;border-radius:6px">ğŸ“° å…¬ä¼—å· (27æ¡)</summary><div class=details-content markdown=1><h4 id=è¯¦ç»†å†…å®¹å‰10æ¡>è¯¦ç»†å†…å®¹ï¼ˆå‰10æ¡ï¼‰</h4><p><strong>1.</strong> â­ <strong>5æœˆæœ€æ–°6+ç”Ÿä¿¡ï¼Œå•ç»†èƒ+ç©ºè½¬åˆ†æMMP1+ è‚¿ç˜¤ç»†èƒå¯¹è‚¿ç˜¤-å…ç–«ç›¸äº’ä½œç”¨çš„å½±å“ï¼Œè¯†åˆ«æŸåŸºå› é˜³æ€§çš„ç»†èƒäºšç¾¤æ˜¯ç›®å‰æµè¡Œçš„å‘æ–‡æ€è·¯ï¼</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šç”Ÿä¿¡å°è¯¾å ‚</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šè‚¿ç˜¤ã€å…ç–«ã€å•ç»†èƒã€ç”Ÿä¿¡</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šç‚¹å‡»æŸ¥çœ‹è¯¦æƒ…</li><li>ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=Mzg3NDE3NTk4MA==&amp;mid=2247503962&amp;idx=3&amp;sn=ce6b570099219a2382d9254a2978c1e1">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>2.</strong> â­ <strong>æœ€æ–°8+ç”Ÿä¿¡ï¼Œç»“åˆå•ç»†èƒ+ç©ºè½¬+ 18 ç§ç¨‹åºæ€§ç»†èƒæ­»ï¼Œç€é‡äºå¯¹é¢„åå’Œå…ç–«æ²»ç–—ç–—æ•ˆçš„é¢„æµ‹åŠåŸºå› åŠŸèƒ½éªŒè¯ï¼</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šç”Ÿä¿¡å°è¯¾å ‚</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šå…ç–«ã€å•ç»†èƒã€ç”Ÿä¿¡</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šç‚¹å‡»æŸ¥çœ‹è¯¦æƒ…</li><li>ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=Mzg3NDE3NTk4MA==&amp;mid=2247503962&amp;idx=4&amp;sn=6164da66f79e380e7a0beebca69b5273">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>3.</strong> â­ <strong>7+ç”Ÿä¿¡ï¼ŒåŸºäºå•ç»†èƒå’Œç©ºè½¬è¯†åˆ«ç”Ÿæ€ä½ç‰¹å¼‚æ€§è½¬å½•å’Œç»†èƒç»„æˆç‰¹å¾ï¼Œè¯†åˆ«å…³é”®åŸºå› å¹¶è¿›è¡ŒéªŒè¯ã€‚æ€è·¯æ–°é¢–ï¼</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šç”Ÿä¿¡å°è¯¾å ‚</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šå•ç»†èƒã€è½¬å½•ç»„ã€ç”Ÿä¿¡</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šç‚¹å‡»æŸ¥çœ‹è¯¦æƒ…</li><li>ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=Mzg3NDE3NTk4MA==&amp;mid=2247503962&amp;idx=1&amp;sn=a84f377c803ce802f7e7fe286560b661">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>4.</strong> â­ <strong>å…ç–«é€ƒé€¸æ–°å‹é©±åŠ¨å› ç´ ï¼å—æ–¹åŒ»ç§‘å¤§å­¦å—æ–¹åŒ»é™¢ï¼šå…‹æœè‚¿ç˜¤å…ç–«è€è¯æ€§çš„ç²¾ç¡®æ²»ç–—ç­–ç•¥</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šè½¬åŒ–åŒ»å­¦ç½‘</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šè‚¿ç˜¤ã€å…ç–«ã€è€è¯</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šé¶å‘ MCUB-PRKN ç›¸äº’ä½œç”¨å¯èƒ½æ˜¯ä¸€ç§ç²¾ç¡®çš„æ²»ç–—ç­–ç•¥ï¼Œä»¥å…‹æœå…ç–«è€è¯æ€§ï¼ŒåŒæ—¶å¯¹æ­£å¸¸ç»„ç»‡çš„æ¯’æ€§æœ€å°ã€‚</li><li>ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=MjM5MzQ4NTk4MA==&amp;mid=2656509853&amp;idx=3&amp;sn=cdca15e2bfa03b16982b331a21e7f8fe">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>5.</strong> <strong>8.3åˆ†è‚ è„‘è½´åˆ›æ–°ç‚¹é€Ÿçœ‹ï¼æš¨å—&åŒ—åŒ»å¤§ã€è‚ é“èŒç¾¤-ä»£è°¢ç‰©-ç‚ç—‡é€šè·¯ã€‘è¿™å¥—æ€è·¯ç›´æ¥ç”¨ï¼</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šç¥ç»å²›</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šä»£è°¢ã€é€šè·¯</li><li>ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=MzkyNzcxMjEyMg==&amp;mid=2247497929&amp;idx=1&amp;sn=8512c1c70f93269bf26fe36cdc6df8a0">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>6.</strong> <strong>æœ€æ–°10åˆ†ç”Ÿä¿¡ï¼Œå•ç»†èƒ+ç©ºè½¬è¯†åˆ«ECM é‡å¡‘ç›¸å…³æˆçº¤ç»´ç»†èƒï¼Œå¹¶ç¡®å®šå…³é”®åŸºå› è¿›è¡Œå®éªŒéªŒè¯ï¼Œå¹²æ¹¿ç»“åˆå€¼å¾—å€Ÿé‰´ï¼</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šç”Ÿä¿¡å°è¯¾å ‚</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šå•ç»†èƒã€ç”Ÿä¿¡</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šç‚¹å‡»æŸ¥çœ‹è¯¦æƒ…</li><li>ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=Mzg3NDE3NTk4MA==&amp;mid=2247503962&amp;idx=2&amp;sn=fe095d9066721adba50d704bf330d7d3">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>7.</strong> <strong>11æœˆ26-27æ—¥åˆè‚¥ï¼è›‹ç™½è¡¨è¾¾ä¸å·¥ç¨‹åŒ–æ”¹é€ ã€åŸºå› ç¼–è¾‘ä¸åŠŸèƒ½ç»„å­¦ã€AI+åˆæˆç”Ÿç‰©å­¦ã€ç”Ÿç‰©å‚¬åŒ–ä¸ç»†èƒå·¥å‚ã€ä»£è°¢ä¸å‘é…µå·¥ç¨‹&mldr;</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šé—²è°ˆ Immunology</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šä»£è°¢ã€åŸºå› ç»„</li><li>ğŸ“ <strong>æè¿°</strong>ï¼š60+ç”Ÿç‰©åˆ¶é€ ä¸“å®¶é½èšï¼Œ800+è¡Œä¸šåŒä»ä¸ä¼šï¼ŒæœŸå¾…ä¸ä¼š~</li><li>ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=Mzg2OTczNjI0OQ==&amp;mid=2247528884&amp;idx=3&amp;sn=86989ef536c0e6da021d74729b6cd792">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>8.</strong> <strong>Natureé‡ç£…ï¼è§£æç™Œç—‡å…ç–«ä¸­çš„æ ‘çªçŠ¶ç»†èƒ</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šç”Ÿä¿¡äºº</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šç™Œç—‡ã€å…ç–«</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šæ ‘çªçŠ¶ç»†èƒæ˜¯è¿æ¥innate å…ç–«ï¼ˆå…ˆå¤©å…ç–«ï¼‰å’Œadaptive å…ç–«ï¼ˆé€‚åº”æ€§å…ç–«ï¼‰çš„å…³é”®æ¢çº½ï¼Œåœ¨è‚¿ç˜¤å…ç–«ä¸­æ—¢</li><li>ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651248533&amp;idx=8&amp;sn=4ead46cde60707be63d8571894cb6cdd">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>9.</strong> <strong>Cancer Cellçªç ´ç»¼è¿°ï¼šç ´è¯‘è‚¿ç˜¤è½¬ç§»æ–°è·¯å¾„</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šç”Ÿä¿¡äºº</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šè‚¿ç˜¤ã€cancer</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šå¾ªç¯è‚¿ç˜¤ç»†èƒï¼ˆCTCsï¼‰ä½œä¸ºç™Œç—‡è½¬ç§»çš„"ç§å­"ï¼Œå…¶æ•è·æŠ€æœ¯ä¸ç”Ÿç‰©å­¦è§£æå¯¹çªç ´æ™šæœŸæ²»ç–—ç“¶é¢ˆã€å¼€å‘ç²¾å‡†å¹²é¢„ç­–ç•¥å…·æœ‰</li><li>ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651248533&amp;idx=4&amp;sn=0488d01525d65f44463f4f7ab83dc8b4">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>10.</strong> <strong>ã€ŠCancer Cellã€‹é‡ç£…ï¼šè·¨15ç§ç»„ç»‡ç™Œç§ï¼Œé¦–åº¦æ­ç§˜ä¸¤ç±»æŠ—åŸå‘ˆé€’ç™Œç—‡æˆçº¤ç»´ç»†èƒç©ºé—´åˆ†å¸ƒå›¾ï¼</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šç”Ÿä¿¡äºº</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šç™Œç—‡ã€cancer</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šè¿‘æ—¥ï¼Œç¾å›½å¾·å…‹è¨æ–¯å¤§å­¦æ•™æˆHuocong HuangåŠå…¶å°ç»„çš„æœ€æ–°ç ”ç©¶æå‡ºå•ç»†èƒåˆ†è¾¨ç‡ä¸‹æŠ—åŸå‘ˆé€’ç™Œç—‡ç›¸å…³æˆçº¤ç»´</li><li>ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651248533&amp;idx=3&amp;sn=a2b31c45a78ac3c79a9ad46883e9809f">æŸ¥çœ‹åŸæ–‡</a></li></ul><blockquote><p>ğŸ’¡ è¯¥æ¥æºè¿˜æœ‰ 17 æ¡å†…å®¹ï¼Œè¯¦è§ <a href=#%E6%9B%B4%E5%A4%9A-%E5%85%AC%E4%BC%97%E5%8F%B7>æ–‡æœ«</a></p></blockquote></div></details><details><summary style="text-align:right;direction:rtl;padding:10px 15px;background:linear-gradient(135deg,#f8f9fa 0%,#e9ecef 100%);border-right:4px solid #667eea;font-weight:600;cursor:pointer;margin:15px 0;border-radius:6px">ğŸ§¬ æ•°æ®å‰æ²¿ (57æ¡)</summary><div class=details-content markdown=1><h4 id=è¯¦ç»†å†…å®¹å‰10æ¡-1>è¯¦ç»†å†…å®¹ï¼ˆå‰10æ¡ï¼‰</h4><p><strong>1.</strong> â­ <strong>GSE308792 åŸºäºå•ç»†èƒRNAæµ‹åºçš„å®«é¢ˆç™Œå…ç–«ç»†èƒäºšç¾¤åŠåŠŸèƒ½ç‰¹å¾åˆ†æ</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€immuneã€sequencing</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensA comprehensive characterization of immune cells within the tumor microenvironment (TME) of cervical squamous cell carcinoma (CSCC) is essential to advance understanding of tumor biology and guide immunotherapy development. Using single-cell RNA sequencing, we analyzed 14,441 immune cells isolated from tumor tissues and paratumor tissues of three CSCC patients. This analysis identified nine major immune cell subsets, including CD8+ T cells, regulatory T cells (Tregs), natural killer/T cells (NK/T cells), B cells, plasmacytoid dendritic cells (pDCs), and macrophages. Notably, elevated CCR7 expression in exhausted CD8+ T cells was associated with improved prognosis, suggesting it as a preliminary candidate for an immunoregulatory target that warrants further investigation. Additionally, CCL5 levels were elevated in Tregs, indicating a possible involvement in their recruitment to the tumor site that requires further validation. By integrating data on tumor suppressors, oncogenic factors, cytokines, and chemokines, we performed differential gene expression analyses across immune populations, identifying candidate genes for further mechanistic investigation. This systematic comparison of the TME between tumor and paratumor tissues reveals dynamic changes in the immune landscape, providing insights and suggesting potential targets for further study to enhance understanding and treatment of CSCC.</li><li>ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE308792">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>2.</strong> â­ <strong>GSE292993 COPD çš„å®è´¨ã€æ°”é“å’Œè¡€ç®¡ç©ºé—´è½¬å½•ç»„å­¦ç‰¹å¾</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šspatialã€spatial transcriptomicsã€transcriptomics</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Joselyn J Rojas-Quintero ; Scott A Ochsner ; Francesca PolverinoSeries Type : OtherOrganism : Homo sapiens ; synthetic constructSpace Profiling for WTA RNA transcriptomics in lung parenchymal, airway, and vessel of COPD and control patients.</li><li>ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE292993">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>3.</strong> â­ <strong>GSE274738 èƒƒç™Œå¹²ç»†èƒå’Œéèƒƒç™Œå¹²ç»†èƒçš„å…¨è½¬å½•ç»„æµ‹åº</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€sequencingã€transcriptome</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Xiaowei Chen ; Qiong Li ; Yanan Wang ; Ai Chen ; Xiaobing ShenSeries Type : Expression profiling by high throughput sequencing ; Non-coding RNA profiling by high throughput sequencingOrganism : Homo sapiensAs a subpopulation of tumor cells with stemness characteristics such as self-renewal ability and high oncogenicity, gastric cancer stem cells (GCSCs) are considered to be tumor-initiating cells and are the root cause of cancer recurrence and chemoresistance. Therefore, an in-depth study of the stemness characteristics and maintenance mechanism of GCSCs is of great significance for the treatment of gastric cancer (GC). In this study, GCSCs and non-gastric cancer stem cells (Non-GCSCs) derived from tumor tissues of GC patients were used for whole transcriptome sequencing. The goal of identifying key differentially expressed circRNAs, lncRNAs, miRNAs and mRNAs associated with GCSCs. In conclusion, we mapped the molecular feathers at RNA level closely related to GCSCs and revealed certain ncRNAs with great research potentia based on the whole transcriptome sequencing.</li><li>ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE274738">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>4.</strong> â­ <strong>GSE273375 æœ€å¤§åŒ–ç™Œç—‡çº³ç±³ç–«è‹—çš„ç–—æ•ˆä»¥åŠå…ç–«ç–—æ³•åº”ç­”è€…å’Œéåº”ç­”è€…ä¸­çš„å…ç–«ç»†èƒå›¾è°±</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€immuneã€regex:immuno(logy|therapy|suppression)</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Xiangxiang Xu ; Lu Diao ; Ao Zhu ; Jin Wang ; Yuhan Liu ; Xianlan Chen ; Yan Zheng ; Jun Zhao ; Mi LiuSeries Type : OtherOrganism : Mus musculusThe therapeutic efficacy of cancer vaccines can be optimized from 3 aspects: adjuvants, vaccine formulation, and processing of tumor antigens. Herein, various different adjuvants, such as toll like receptors and STING agonists etc., and their combinations were compared in cancer nanovaccines loaded with whole tumor antigens were illustrated. By comparing different sized nanovaccines and micronvaccines, 200nm-400nm and 2.5Î¼m were discovered to be optimal sizes of nanovaccines and micronvaccines. Rapid freezing, fixation, heating, salting-out, ethanol precipitate can affect the immunogenicity of tumor antigens and efficacy of cancer vaccines. The optimal cancer vaccine can cure all or most tumor-bearing body in melanoma mouse model, lung cancer mouse model, subcutaneous pancreatic cancer model, orthotopic pancreatic cancer model, melanoma lung metastasis model. In addition, the immune cell profiles were systematically investigated using single-cell sequencing, in blood, splenocytes and draining lymph nodes of healthy mice, PBS treated tumor-bearing mice, vaccine-treated non-cured mice and cured mice after different time. By comparing 21 samples, some featured clusters and markers, such as S100A4, KLRG1, SIPR5, CXCR3, IL2Ra, IKZF2, CX3CR1, S100A8, and S100A9 etc., were identified to distinguish responders and non-responders to immunotherapy. These biomarkers were verified and confirmed the feasibility of predicting therapeutic efficacy in mouse cancer model and cancer patients. In summary, this study presented a method to optimize cancer nanovacines from different aspects, systematically investigated immune cell profiles in non-responders and responders to immunotherapy, and discovered some featured biomarkers for predicting or distinguishing responders and non-responders to immunotherapy.</li><li>ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE273375">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>5.</strong> â­ <strong>GSE309938 EBV+ ä¸ EBV- èƒƒç™Œä¸­åœ°è¥¿ä»–æ»¨æ²»ç–—åé€šè·¯æ¿€æ´»çš„è½¬å½•ç»„åˆ†æ [RNA-Seq]</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€RNA-seqã€pathway</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Yin Wang ; Benjamin E GewurzSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensEpstein-Barr virus associated gastric cancer (EBVaGC) accounts for âˆ¼9â€“10% of gastric cancers worldwide and is defined by a distinctive molecular profile, including extreme hypermethylation of the DNA. Targeting this aberrant methylation may be a potential therapeutic strategy. EBV âº gastric cancer cell lines (YCCEL1, SNU719) and EBV â» lines (AGS, SNU16, HGC27) were treated with a DNA methyl-transferase inhibitor (DNMT), decitabine (DCB), for three days followed by RNA sequencing to identify EBV-specific responses.</li><li>ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE309938">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>6.</strong> <strong>GSE307857 BRG1 ç¼ºå¤±åœ¨è‚ºç™Œä¸­å¾ˆå¸¸è§ï¼Œå¹¶é€šè¿‡è½¬å½•å’Œè¡¨è§‚é—ä¼ é‡ç¼–ç¨‹æ”¹å˜è‚ºä¸Šçš®ç»†èƒã€‚</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€epigenetic</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Mathewos Tessema ; Christin M Yingling ; Loryn M Phillips ; Kieu Do ; Maria A Picchi ; Randy Willink ; Steven A BelinskySeries Type : Methylation profiling by genome tiling arrayOrganism : Homo sapiensBackground/Objectives: BRG1 loss-of-function (LOF) mutation is found in ~10% non-small cell lung cancer (NSCLC) but its role in lung tumorigenesis is unclear and investigated in this study. Methods: BRG1-knockout (KO) lines were generated from various non-malignant, pre-malignant, and malignant human lung epithelia-derived cell lines using CRISPR. Effects of BRG1-KO on cell growth, transcriptome, methylome, and epigenetic therapy were compared with wild-type (BRG1-WT) isogenic controls using standard in vitro and in vivo assays. Results: BRG1 protein was expressed in all non/pre-malignant lung epithelial cells but lost in 47% (14/30) of NSCLC cell lines. BRG1-KO and cigarette smoke (CS) exposure individually transformed human bronchial epithelial cell lines (HBECs) as evident by anchorage-independent growth. BRG1-KO and CS produced additive to synergistic effects on sensitivity to transformation that differed across HBECs. RNA-seq analysis revealed BRG1-KO significantly changed expression of over 8,500 genes on average impacting lung development, function, damage repair and cancer pathways including axonal guidance, pulmonary wound healing, and epithelial-to-mesenchymal transition (EMT). BRG1-KO also led to hypermethylation of >47,000 promoter CpGs within ~9,500 genes on average in different HBECs that included silencing of epithelial genes involved in EMT and tumor suppressor genes. BRG1-KO also moderately increased the in vitro and in vivo sensitivity of NSCLC cells to some epigenetic drugs. Conclusion: BRG1-LOF is frequent in NSCLC, can drive transformation of lung epithelial cells to acquire properties of premalignant cells indicating a potential role in lung cancer initiation, and sensitizes lung tumors to epigenetic therapy.</li><li>ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE307857">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>7.</strong> <strong>GSE305006 ç”¨äºæ¨¡æ‹Ÿå¿ƒè„æŸä¼¤å’Œç–¾ç—…ä¸­å…ç–«åŠ¨åŠ›å­¦çš„äººç±»å¤šå™¨å®˜ç±»å™¨å®˜å¹³å°</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šimmuneã€cardiac</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Jasmeet S Reyat ; Yuqi Shen ; Gowishan Poologasundarampillai ; Amirpasha Moetazedian ; Julie Rayes ; Abdullah O KhanSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensWe devised a microphysiological system (MPS) coupling comBOs (combined bone and bone marrow organoids) and VCOs (vascularised cardiac organoids), enabling the recruitment of immune cells to VCOs follwing ischemic injury. Ischemia was modelled by exposing VCOs to hypoxic culture conditions (1% O2 for 24 hrs) before co-culture in our MPS. single nuclear RNA-sequencing was used to assess fibrosis and immune cell infiltration after cardiac injury.</li><li>ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE305006">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>8.</strong> <strong>GSE301405 DNAç”²åŸºåŒ–ç´Šä¹±å¯¼è‡´ATRTä¸­å¯é¶å‘è½¬å½•å¯å¡‘æ€§[RNA-seq]</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šRNA-seqã€methylation</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Michael A. Koldobskiy ; Ashley R. TetensSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensAtypical teratoid rhabdoid tumor (ATRT) is a highly aggressive but genetically simple pediatric central nervous system tumor, defined by biallelic inactivation of the chromatin regulator SMARCB1 with remarkably few other cooperating mutations. Despite its genetic homogeneity, ATRT exhibits profound clinical and epigenetic heterogeneity, with three major subgroups (ATRT-TYR, ATRT-MYC, and ATRT-SHH) defined by DNA methylation and transcriptional signatures. Beyond these subgroup-defining features, we aimed to investigate epigenetic variability within tumors by applying whole-genome bisulfite sequencing and probabilistic modeling to quantify stochastic DNA methylation in primary ATRT samples encompassing all three subgroups. We show that ATRT exhibits a destabilized and increasingly stochastic methylome. While ATRT global methylation patterns diverge according to subgroup, some methylation perturbations, such as hypermethylation and increased methylation entropy over bivalent promoters, are consistent across subgroups. We find that methylation stochasticity alterations map onto potential drivers of ATRT, such as LIN28a, the HOXD cluster for ATRT-MYC, and OTX2 for ATRT-TYR, and identify actionable targets, such as hypermethylation of the tumor suppressor CDKN2a across all subgroups. We investigate the sensitivity of the aberrant DNA methylation landscape of ATRT to pharmacologic DNA methyltransferase inhibition and histone deacetylase inhibition (HDACi). We show that decitabine leads to profound demethylation of patient-derived ATRT cell lines, including reversal of hypermethylation at bivalent promoters and the CDKN2a locus. The addition of HDACi leads to dramatic gene expression changes, including upregulation of innate immune signaling pathways, such as STING/interferon signaling, genes under the regulation of bivalent promoters, and reactivation of the tumor suppressor CDKN2A. The combination of DNMTi and HDACi synergistically reduces cell viability. Taken together, we show that ATRT has a highly stochastic methylome sensitive to epigenetic manipulation.</li><li>ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE301405">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>9.</strong> <strong>GSE298745 åŸºäºè¡€æ¸…å¤–æ³Œä½“microRNAçš„äººå·¥æ™ºèƒ½è¯Šæ–­æ¨¡å‹å¯é«˜ç²¾åº¦æ£€æµ‹è‚ç»†èƒç™Œ[RNA-seq]</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcarcinomaã€RNA-seq</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Dae-Soo Kim ; Sugi Lee ; Tae-Su HanSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusRNA sequencing was performed on mouse liver tissue samples from four groups: ND+oil (normal), WD+oil (NASH), ND+CClâ‚„ (cirrhosis), and WD+CClâ‚„ (HCC).</li><li>ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE298745">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>10.</strong> <strong>GSE295777 è½¬å½•å› å­ Yin-Yang 1 è°ƒæ§å¿ƒè„ä»£è°¢é‡ç¼–ç¨‹ä»¥åº”å¯¹è¿åŠ¨æˆ–ç—…ç†åº”æ¿€</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šmetabolicã€cardiac</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Manling Zhang ; Zishan Peng ; Haiqing Ping ; Zoe Li ; Jia-Jun Liu ; Silvia Liu ; Ning FengSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusThe pleiotropic transcription factor Yin Yang 1 (YY1) regulates cellular metabolism in a stage- and tissue-dependent manner. However, its role in cardiac energetic regulation remains unclear. We found that cardiac-specific YY1 knockout (cYY1 KO) mice exhibited cardiac dysfunction after two weeks of swimming exercise, suggesting an impaired adaptive cardiac response. Further analysis revealed that exercise-induced upregulation of transcription factor networks controlling cardiac metabolism, including peroxisome proliferator-activated receptor gamma coactivator 1 alpha (PGC-1Î±), was blunted in cYY1 KO mice. Consistently, citrate synthase activity, an indicator of mitochondrial content, was reduced in these mice. In response to transaortic constriction (TAC), cYY1 KO mice developed significantly exacerbated heart failure. RNA sequencing showed downregulation of metabolic genes and pathways, including PGC-1Î±, in TAC cYY1 KO mice hearts. Additionally, mitochondrial complex protein levels and complex I activity were reduced, consistent with suppressed metabolic gene transcription. Previously, we observed increased YY1 expression in hearts subjected to both exercise and TAC. However, while cardiac metabolism was enhanced with exercise, it was impaired with TAC. We found that p300 binding to YY1 increased during exercise, whereas histone deacetylase 3 (HDAC3) binding to YY1 increased in TAC hearts. These findings suggest that YY1-mediated transcriptional regulation of metabolic genes is modulated by the epigenetic regulators p300 and HDAC3.</li><li>ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE295777">æŸ¥çœ‹åŸæ–‡</a></li></ul><blockquote><p>ğŸ’¡ è¯¥æ¥æºè¿˜æœ‰ 47 æ¡å†…å®¹ï¼Œè¯¦è§ <a href=#%E6%9B%B4%E5%A4%9A-%E6%95%B0%E6%8D%AE%E5%89%8D%E6%B2%BF>æ–‡æœ«</a></p></blockquote></div></details><details><summary style="text-align:right;direction:rtl;padding:10px 15px;background:linear-gradient(135deg,#f8f9fa 0%,#e9ecef 100%);border-right:4px solid #667eea;font-weight:600;cursor:pointer;margin:15px 0;border-radius:6px">ğŸ§ª åšå®¢æ›´æ–° (1æ¡)</summary><div class=details-content markdown=1><h4 id=è¯¦ç»†å†…å®¹å…¨éƒ¨1æ¡>è¯¦ç»†å†…å®¹ï¼ˆå…¨éƒ¨1æ¡ï¼‰</h4><p><strong>1.</strong> <strong>æ–°è‹±æ ¼å…°ç”Ÿç‰©å®éªŒå®¤Â®æ¨å‡ºNEBNextÂ®ç”²å‹æµæ„Ÿç—…æ¯’é›†æˆç´¢å¼•å¼•ç‰©æ¨¡å—ï¼Œä»¥æ¨è¿›ç”²å‹æµæ„Ÿç—…æ¯’çš„ç›‘æµ‹å’Œæµ‹åºã€‚</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šsequencing</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šA new integrated indexing workflow accelerates high-throughput Influenza A sequencing, enabling rapid RNA sequencing for global&mldr;</li><li>ğŸ”— <a href=https://www.rna-seqblog.com/new-england-biolabs-launches-the-nebnext-flu-a-integrated-indexing-primer-module-to-advance-influenza-a-surveillance-and-sequencing/>æŸ¥çœ‹åŸæ–‡</a></li></ul></div></details><h2 id=-å…³é”®è¯ç»Ÿè®¡>ğŸ“Š å…³é”®è¯ç»Ÿè®¡</h2><table><thead><tr><th>å…³é”®è¯</th><th>å‡ºç°æ¬¡æ•°</th></tr></thead><tbody><tr><td>cancer</td><td>17</td></tr><tr><td>å•ç»†èƒ</td><td>10</td></tr><tr><td>RNA-seq</td><td>8</td></tr><tr><td>å…ç–«</td><td>7</td></tr><tr><td>sequencing</td><td>7</td></tr><tr><td>immune</td><td>6</td></tr><tr><td>ç”Ÿä¿¡</td><td>5</td></tr><tr><td>è‚¿ç˜¤</td><td>5</td></tr><tr><td>Neuronal</td><td>4</td></tr><tr><td>ä»£è°¢</td><td>3</td></tr><tr><td>single-cell</td><td>3</td></tr><tr><td>pathway</td><td>3</td></tr><tr><td>methylation</td><td>3</td></tr><tr><td>carcinoma</td><td>3</td></tr><tr><td>scRNA</td><td>3</td></tr><tr><td>genome</td><td>3</td></tr><tr><td>ç™Œç—‡</td><td>3</td></tr><tr><td>é€šè·¯</td><td>2</td></tr><tr><td>ChIP-seq</td><td>2</td></tr><tr><td>RNAseq</td><td>2</td></tr></tbody></table><hr><h2 id=-æ›´å¤šå†…å®¹>ğŸ“ æ›´å¤šå†…å®¹</h2><details><summary><a name=æ›´å¤š-å…¬ä¼—å·></a>ğŸ“° å…¬ä¼—å· å…¶ä»–å†…å®¹ (17æ¡)</summary><div class=details-content markdown=1><ul><li><a href="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651248533&amp;idx=1&amp;sn=e2806dbc8a4365597a85f0fe4136de11">å¼ æ³½æ°‘é™¢å£«å›¢é˜ŸCancer Cell æ–°ä½œï¼Œé‡å¡‘è‚¿ç˜¤å…ç–«æ–°æœºåˆ¶</a></li><li><a href="https://mp.weixin.qq.com/s?__biz=Mzg2OTU2MzM2NA==&amp;mid=2247493016&amp;idx=1&amp;sn=d06cbc80a3da957b9c8a721dbfb27e10">æ°¨åŸºé…¸ä»£è°¢æ˜¯çœŸçš„ç«ï¼Œå¹²æ¹¿ç»“åˆè½»æ¾å‘7.5åˆ†2åŒºæ–‡ç« ã€‚ç°åœ¨ä¸‹æ‰‹è¿˜ä¸æ™šï¼</a></li><li><a href="https://mp.weixin.qq.com/s?__biz=MzI1Njk4ODE0MQ==&amp;mid=2247533650&amp;idx=1&amp;sn=0cc5d033481f1317656ecdbe650375b4">PhicluståŒ…åŸºäºç»†èƒèšç±»çº¯åº¦åˆ†æ</a></li><li><a href="https://mp.weixin.qq.com/s?__biz=MzUzMTEwODk0Ng==&amp;mid=2247538070&amp;idx=1&amp;sn=76c354c9fdafa0bdd8cdb144e06b7380">SATURNè·¨ç‰©ç§å•ç»†èƒæ•°æ®é›†æ•´åˆå®ç° Â· ç»­</a></li><li><a href="https://mp.weixin.qq.com/s?__biz=Mzg5MDk3Mzg4OA==&amp;mid=2247498473&amp;idx=1&amp;sn=586e1b0866005a66abd773dac666673d">å•ç»†èƒä¹‹æ‰¾å¯»å—å½±å“æœ€å¤§çš„ç»†èƒç±»å‹ï¼ŒAuguræ¥å¸®å¿™å•¦_</a></li><li><a href="https://mp.weixin.qq.com/s?__biz=MzkwMzY2NjkwNg==&amp;mid=2247495547&amp;idx=1&amp;sn=5f99b53bbad8a17968947a7e6e0b19cf">å­¦ç”Ÿä¿¡ï¼Œæœ€é‡è¦çš„æ˜¯æœ‰äººèƒ½å¸®ä½ ç­”ç–‘ï¼Œå®æ—¶è§£å†³ä½ çš„é—®é¢˜ï¼Œè¿™æ ·è¿›æ­¥æ‰å¿«</a></li><li><a href="https://mp.weixin.qq.com/s?__biz=Mzg2NDcxMzYwNg==&amp;mid=2247490604&amp;idx=1&amp;sn=b3b42a38138e71f1ae7476439aacc7c5">è¿™ç¯‡NCçš„å•ç»†èƒå·®å¼‚åˆ†ææ–¹æ³•è¯„æµ‹å¾ˆç»å…¸ï¼Œå€¼å¾—å­¦ä¹ ï¼šä»æ–¹æ³•é€‰æ‹©åˆ°ç»“æœè§£è¯»ï¼Œè®©ä½ ä¸å†â€œé€‰æ‹©å›°éš¾â€ï¼Œå‡å°‘å‡é˜³æ€§</a></li><li><a href="https://mp.weixin.qq.com/s?__biz=MzI4ODc5MDI5NA==&amp;mid=2247503498&amp;idx=1&amp;sn=613597e7069f26a3f598b9c69901fd78">ã€Šç§‘å­¦ã€‹ï¼šæŠ—ç™Œå…ç–«æœºåˆ¶å¤§çªç ´ï¼è¥¿æ¹–å¤§å­¦å›¢é˜Ÿæ‰¾åˆ°æ ‘çªç»†èƒå‘ˆé€’æŠ—åŸã€æ¿€æ´»Tç»†èƒçš„å…³é”®åˆ†å­</a></li><li><a href="https://mp.weixin.qq.com/s?__biz=MzAwMzY4MTYxNw==&amp;mid=2655821380&amp;idx=4&amp;sn=797f7d4a2f8e3ab334b80cebf01675d2">å›½è‡ªç„¶ç ”ç©¶ç»†èƒè¡°è€ï¼Œåšå‡ºæ–°æ„çš„ä¸‰ä¸ªè§’åº¦â€¦â€¦</a></li><li><a href="https://mp.weixin.qq.com/s?__biz=MzkzODIxMDY5NQ==&amp;mid=2247507164&amp;idx=2&amp;sn=8df4e66b2242be009dcd286d91205f8c">Scienceä¸¨è‘£æ™¨å›¢é˜Ÿå‘ç°å”¤é†’å…ç–«ç³»ç»Ÿâ€œè¶…çº§å“¨å…µâ€çš„å…³é”®åˆ†å­Ms4a7</a></li><li><a href="https://mp.weixin.qq.com/s?__biz=MzkyNDI1MzE0NA==&amp;mid=2247490132&amp;idx=1&amp;sn=9237431513e5ce7d8989fab47d1945e4">BiomarkerMLï¼šç”Ÿç‰©æ ‡å¿—ç‰©å‘ç°çš„è›‹ç™½è´¨ç»„å­¦æœºå™¨å­¦ä¹ å·¥ä½œæµ</a></li><li><a href="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651248533&amp;idx=7&amp;sn=3e2a0d1b02cc8e1de0477644568c5637">Cellå†æ·»æŠ—ç™Œæ–°æ˜Ÿï¼ŒAOAHæ”¹å†™ç™Œç—‡æ²»ç–—è§„åˆ™ï¼</a></li><li><a href="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651248533&amp;idx=6&amp;sn=4fa8f71f0f6a664b7d6746a741ad5537">ç™»é¡¶topçº§æœŸåˆŠï¼GWAS+å•ç»†èƒåˆ†æè§£å¯†ç–¾ç—…æœºåˆ¶ï¼Œè¿™æ³¢æ€è·¯å¿…é¡»å­¦ï¼</a></li><li><a href="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651248533&amp;idx=5&amp;sn=113bfc37eada1403c84e004b5d90e789">ä¸­å›½åŒ»å­¦ç§‘å­¦é™¢æ—ä¸œæ˜•é™¢å£«ç­‰å›¢é˜Ÿ50+çªç ´ï¼ç»å…¸é€šè·¯é¦–æ¬¡è§£é”é£Ÿç®¡é³ç™Œå‘½é—¨ï¼</a></li><li><a href="https://mp.weixin.qq.com/s?__biz=MjM5MzQ4NTk4MA==&amp;mid=2656509853&amp;idx=1&amp;sn=34b2408001b9b733eee05c5854c4ad26">èƒƒç™Œæ²»ç–—æ–°æ€è·¯ï¼ä¸­å±±å¤§å­¦è‚¿ç˜¤é˜²æ²»ä¸­å¿ƒå¾ç‘å/é æ€€å¼ºå›¢é˜Ÿé¦–æ¬¡æ­ç¤ºTGF-Î²æŠ‘åˆ¶è‚¿ç˜¤ç”Ÿé•¿çš„åˆ†å­æœºåˆ¶ï¼Œæå‡ºåŒé‡é¶å‘æ²»ç–—æ–°ç­–ç•¥</a></li><li><a href="https://mp.weixin.qq.com/s?__biz=MzU1MDk1NTY5MA==&amp;mid=2247540960&amp;idx=1&amp;sn=f50e41b94d5ad4f58549878cb30af6e2">æé€Ÿã€å¢æ•ˆã€æ›´å¼ºå¤§ï½œXeniumè½¯ä»¶å‡çº§ï¼Œèµ‹èƒ½å•ç»†èƒç©ºé—´æˆåƒæ–°é«˜åº¦ï¼</a></li><li><a href="https://mp.weixin.qq.com/s?__biz=Mzg2MDY1NTYyOQ==&amp;mid=2247498944&amp;idx=1&amp;sn=4568a97d529472b7d5017eed0b110fc4">å†…å®¹å¤ä¹ &mdash;å•ç»†èƒç©ºé—´åˆ†æä¹‹NMF</a></li></ul></div></details><details><summary><a name=æ›´å¤š-æ•°æ®å‰æ²¿></a>ğŸ§¬ æ•°æ®å‰æ²¿ å…¶ä»–å†…å®¹ (47æ¡)</summary><div class=details-content markdown=1><ul><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE282803">GSE282803 KMT2D é€šè¿‡æš‚æ—¶æ¿€æ´»ç¥ç»å…ƒè½¬å½•å› å­åŸºå› æ¥æ§åˆ¶å°è„‘é¢—ç²’ç»†èƒåˆ†åŒ– [RNA-seq]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE262167">GSE262167 s-è…ºè‹·ç”²ç¡«æ°¨é…¸ (SAM) é¥®é£Ÿå†³å®šåä»£è¡¨è§‚é—ä¼ ä¿®é¥°å’Œä»£é™…å…ç–«ååº”ã€‚</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE261489">GSE261489 å•ç»†èƒæµ‹åºæ­ç¤ºå¤§é¼ çš®ä¸‹ç­‹è†œä¸­ä¸€ç§æ–°å‹é—´å……è´¨ç»†èƒç°‡</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE208307">GSE208307 é€šè¿‡é¶å‘ HCC ä¸­çš„ç™Œç—‡ USP14 å®ç° CD8+ T ç»†èƒä¾èµ–æ€§æ€ä¼¤ä½œç”¨ [scRNA-seq]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE309844">GSE309844 ä¸¤æ –æ¤ç‰©æ°´è—¤çš„å•ç»†èƒè½¬å½•ç»„æ•°æ®é›†</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE307412">GSE307412 æœ‰ä¸åˆ†è£‚æœŸé—´ SOX2 ç£·é…¸åŒ–é™åˆ¶åŸºå› ç»„æŸä¼¤ [ChIP-Seq 2]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE298268">GSE298268 Atg5 æ•²é™¤ä¸‹è°ƒ erastin2 å¤„ç†çš„åŸä»£ PTEC ä¸­çš„ KEGG é€šè·¯â€œæ°§åŒ–ç£·é…¸åŒ–â€</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE277316">GSE277316 æœ‰ä¸åˆ†è£‚æœŸé—´ SOX2 ç£·é…¸åŒ–é™åˆ¶åŸºå› ç»„æŸä¼¤ [ChIP-Seq]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE276865">GSE276865 æœ‰ä¸åˆ†è£‚æœŸé—´ SOX2 ç£·é…¸åŒ–é™åˆ¶åŸºå› ç»„æŸä¼¤ [ATAC-Seq]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE276848">GSE276848 æœ‰ä¸åˆ†è£‚æœŸé—´ SOX2 ç£·é…¸åŒ–é™åˆ¶åŸºå› ç»„æŸä¼¤ [RNA-Seq]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE309926">GSE309926 ä¸åŒæ¡ä»¶ä¸‹å°é¼ éª¨é«“åŸ¹å…»äº§ç”Ÿçš„å¸¸è§„æ ‘çªçŠ¶ç»†èƒçš„RNAæµ‹åº</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE309882">GSE309882 å¤šé‡é¢„å¤„ç†ç™½è¡€ç—…ä¸­MeninæŠ‘åˆ¶å‰‚çš„ç›´æ¥è€è¯æ€§</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE307589">GSE307589è½¬å½•ç»„å­¦æ­ç¤ºäº†å—æ–¹æ¯”ç›®é±¼ï¼ˆParalichthys lethostigmaï¼‰å¹¼ä½“å’Œå¹¼é±¼å‘è‚²åŠå˜æ€çš„è°ƒæ§æœºåˆ¶</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE307180">GSE307180 è½¬å½•ç»„åˆ†æå’Œå®éªŒéªŒè¯æ­ç¤ºäº† PI3K/AKT ä¿¡å·é€šè·¯å‚ä¸é«˜æµ·æ‹”è®¤çŸ¥åŠŸèƒ½éšœç¢ [6_OHG]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE304295">GSE304295 è…ºç—…æ¯’E1Aå¯¹å¥¥æ²™åˆ©é“‚æ•æ„Ÿå’Œè€è¯çš„äººç»“ç›´è‚ ç™ŒHCT116ç»†èƒå¥¥æ²™åˆ©é“‚ååº”çš„å½±å“</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE301412">GSE301412 DNAç”²åŸºåŒ–ç´Šä¹±å¯¼è‡´ATRTä¸­å¯é¶å‘è½¬å½•å¯å¡‘æ€§[WGBS]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE301410">GSE301410 DNAç”²åŸºåŒ–ç´Šä¹±å¯¼è‡´ATRT[WGBSç»†èƒç³»]ä¸­å¯é¶å‘çš„è½¬å½•å¯å¡‘æ€§</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE299994">GSE299994 å¯¹å¯¹ç…§ç»„å°é¼ æˆ–é•¿æœŸé˜¿é­é…¸å¤„ç†å°é¼ çš„é€ è¡€å¹²ç»†èƒè¿›è¡Œ RNA æµ‹åº</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE298588">GSE298588 åŸºäºè¡€æ¸…å¤–æ³Œä½“microRNAçš„äººå·¥æ™ºèƒ½è¯Šæ–­æ¨¡å‹å¯é«˜ç²¾åº¦æ£€æµ‹è‚ç»†èƒç™Œ</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE296150">GSE296150 æŠ‘åˆ¶å®¤æ—æ ¸ä¸­çš„ Ephrin å—ä½“ä¿¡å·ä¼ å¯¼å¯é€šè¿‡è°ƒèŠ‚çªè§¦å¯å¡‘æ€§å’Œå…ç–«ç¨³æ€æ¥å‡è½»é“¶å±‘ç—…</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE290640">GSE290640 CCDC137 æ•²ä½å¯¹è†€èƒ±ç™Œç»†èƒ T24 åŸºå› è¡¨è¾¾çš„å½±å“ã€‚</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE290435">GSE290435 ç¯å¢ƒç›¸å…³é“…æš´éœ²å½±å“SH-SY5Yç»†èƒç¥ç»å…ƒåˆ†åŒ–è¿‡ç¨‹ä¸­çš„åŸºå› è¡¨è¾¾</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE287381">GSE287381 SF3A3é€šè¿‡å¢å¼ºc-FOSè¡¨è¾¾é©±åŠ¨å­å®«å†…è†œç™Œçš„è‚¿ç˜¤å‘ç”Ÿï¼Œå¹¶ä»£è¡¨ä¸€ä¸ªæ½œåœ¨çš„æ²»ç–—é¶ç‚¹</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE287111">GSE287111 äººç±»å…ç–«è‚ºç±»å™¨å®˜æ¨¡å‹ç”¨äºç ”ç©¶ SARS-CoV-2 æ„ŸæŸ“åå·¨å™¬ç»†èƒä»‹å¯¼çš„è‚ºç»†èƒè¡°è€ [scRNA-seq]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE286888">GSE286888 é¡ºé“‚æˆ–CX-5461å¤„ç†ä¸‹é«˜çº§åˆ«æµ†æ¶²æ€§åµå·¢ç™Œç»†èƒçš„åŸºå› è¡¨è¾¾è°±æ¯”è¾ƒ</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE286045">GSE286045 ç–«è‹—æ¥ç§å’Œå¹´é¾„å¯¹æ°´ç—˜-å¸¦çŠ¶ç–±ç–¹ç—…æ¯’gEæŠ—åŸç‰¹å¼‚æ€§Tç»†èƒè¿›è¡Œå•ç»†èƒæµ‹åº</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE284266">GSE284266 èƒ†å›ºé†‡25-ç¾ŸåŒ–é…¶å¢å¼ºç»“ç›´è‚ ç™Œä¸­é«“æºæ€§æŠ‘åˆ¶ç»†èƒçš„å…ç–«æŠ‘åˆ¶åŠŸèƒ½</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE282804">GSE282804 KMT2D é€šè¿‡æ—¶é—´æ€§æ¿€æ´»ç¥ç»å…ƒè½¬å½•å› å­åŸºå› æ¥æ§åˆ¶å°è„‘é¢—ç²’ç»†èƒåˆ†åŒ–</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE282802">GSE282802 KMT2D é€šè¿‡æš‚æ—¶æ¿€æ´»ç¥ç»å…ƒè½¬å½•å› å­åŸºå› æ¥æ§åˆ¶å°è„‘é¢—ç²’ç»†èƒåˆ†åŒ– [CUT&amp;RUN]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE281987">åˆ©ç”¨ GSâ€‹â€‹E281987 RNA-seq ç¡®å®š Ctrl-EVs å’Œ M. bovis NX2-EVs çš„ miRNA è¡¨è¾¾è°±ã€‚</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE281311">GSE281311 åœ°å¡ç±³æ¾è¯±å¯¼å‘è‚²ä¸­éª¨éª¼éª¨æ¯’æ€§çš„æœºåˆ¶ï¼šå•ç»†èƒè§†è§’</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE281279">GSE281279 miRNA26b æ•²é™¤å¯¹è¡€ç®¡é’™åŒ–çš„å½±å“ [RNA-seq]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE281028">GSE281028 miRNA26b æ•²é™¤å¯¹è¡€ç®¡é’™åŒ–çš„å½±å“ [scRNA-seq]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE280807">GSE280807 å…·æœ‰è‡ªä½“ç»„ç»‡é©»ç•™å·¨å™¬ç»†èƒå…ç–«å¾®ç¯å¢ƒçš„è‡ªç»„ç»‡äººç±»å¿ƒè„ç±»å™¨å®˜</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE279534">GSE279534 PTEN æ˜¯é™è„‰æ€§è…¿éƒ¨æºƒç–¡éš¾æ„ˆåˆè¡¨å‹çš„ä¸»è¦é©±åŠ¨å› ç´ ï¼Œå®ƒæŠ‘åˆ¶å…ç–«ååº”ã€è¡€ç®¡ç”Ÿæˆå’Œæ·‹å·´ç®¡ç”Ÿæˆã€‚</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE275955">GSE275955 äººç±»ä¹³è…ºç™Œ FFPT ç»„ç»‡çš„ BulkRNA åºåˆ—ï¼›TLS ç¼ºä¹å’Œ TLS ä¸°å¯Œçš„</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE267761">GSE267761 è‚¿ç˜¤å¤–æ³Œä½“åŠ å‰§å¿ƒè‚Œç¼ºè¡€/å†çŒæ³¨æŸä¼¤ä¸­çš„çº¿ç²’ä½“æŸä¼¤</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE228833">GSE228833 A549ç»†èƒä¸­flagï¼ˆETV4ï¼‰çš„å…¨åŸºå› ç»„é¶å‘</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE208308">GSE208308 é€šè¿‡é¶å‘è‚ç»†èƒç™Œä¸­çš„ç™Œç—‡ USP14 å®ç° CD8+ T ç»†èƒä¾èµ–æ€§æ€ä¼¤ä½œç”¨</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE208306">GSE208306 é€šè¿‡é¶å‘ HCC ä¸­çš„ç™Œç—‡ USP14 å®ç° CD8+ T ç»†èƒä¾èµ–æ€§è‡´æ­»æ€§ [CRISPR ç­›é€‰]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE302553">GSE302553 æ‰©å¼ å‹å¿ƒè‚Œç—…ä¸­è‚Œè‚‰ç‰¹å¼‚æ€§æ ¸ç³–ä½“çš„è‡´ç—…æœºåˆ¶ï¼ˆAC16 RNA-seqï¼‰</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE293958">GSE293958 å•æ ¸ RNA æµ‹åºæ­ç¤ºå°è‚ åˆ‡é™¤æœ¯å¼•èµ·çš„è‚æŸä¼¤ä¸­ç‹¬ç‰¹çš„è‚ç»†èƒç¾¤</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE309843">GSE309843 RNAæµ‹åºæ•°æ®åŒ…æ‹¬ï¼šå–‚é£Ÿé«˜è„‚é¥®é£Ÿ4ä¸ªæœˆçš„é‡ç”Ÿå‹ï¼ˆWTï¼‰å’ŒAKOå°é¼ ï¼Œå–‚é£Ÿé«˜è„‚é¥®é£Ÿ4ä¸ªæœˆåæ³¨å°„è½½ä½“å’Œä¸‰è‹¯æ°§èƒºçš„æ¡ä»¶æ€§äººèƒ°æ·€ç´ è¡¨è¾¾å°é¼ ï¼Œä»¥åŠå–‚é£Ÿé«˜è„‚é¥®é£Ÿ2ä¸ªæœˆçš„é‡ç”Ÿå‹ï¼ˆWTï¼‰å°é¼ çš„å‰é¢çš®è´¨RNAæµ‹åºæ•°æ®ã€‚</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE304980">GSE304980 åˆ©ç”¨ CUT&amp;Tag æŠ€æœ¯åœ¨ NIH/3T3 ç»†èƒä¸­å¯¹ Xap5 å’Œ Nono ç»“åˆä½ç‚¹è¿›è¡Œå…¨åŸºå› ç»„å®šä½</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE297252">GSE297252 circ72039 è¿‡è¡¨è¾¾å¯¹èƒ°è…ºç™Œç»†èƒç³»ä¸­å‰è¥¿ä»–æ»¨æ•æ„Ÿæ€§ç›¸å…³åŸºå› è¡¨è¾¾çš„å½±å“</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE282008">GSE282008 æ›²é©¬å¤šé€šè¿‡ ATF4 è¯±å¯¼ä¹³è…ºç™Œç»†èƒå‘ç”Ÿå‰¯å‡‹äº¡</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE279782">GSE279782 å¤šå‘æ€§éª¨é«“ç˜¤ç»†èƒä¸­FOXM1è¡¨è¾¾çš„å…¨åŸºå› ç»„ç­›é€‰</a></li></ul></div></details><hr><p><em>ğŸ“… æŠ¥å‘Šç”Ÿæˆæ—¶é—´ï¼š2025-11-15 21:36</em><br><em>ğŸ¤– ç”± GitHub Actions è‡ªåŠ¨ç”Ÿæˆ</em></p></div><footer class=post__footer><div class="post__tags tags clearfix"><svg class="tags__badge icon icon-tag" width="16" height="16" viewBox="0 0 32 32"><path d="M4 0h8s2 0 4 2l15 15s2 2 0 4L21 31s-2 2-4 0L2 16s-2-2-2-4V3s0-3 4-3m3 10a3 3 0 000-6 3 3 0 000 6"/></svg><ul class=tags__list><li class=tags__item><a class="tags__link btn" href=../../../tags/research/ rel=tag>Research</a></li><li class=tags__item><a class="tags__link btn" href=../../../tags/daily/ rel=tag>Daily</a></li><li class=tags__item><a class="tags__link btn" href=../../../tags/week462025/ rel=tag>Week462025</a></li></ul></div></footer></article></main><div class="authorbox clearfix"><div class=authorbox__header><span class=authorbox__name>About Bloger</span></div></div><nav class="pager flex"><div class="pager__item pager__item--prev"><a class=pager__link href=../../../posts/dailyreports/2025-11-15/ rel=prev><span class=pager__subtitle>Â«&#8201;Previous</span><p class=pager__title>ç§‘ç ”æ—¥æŠ¥ 2025-11-15</p></a></div><div class="pager__item pager__item--next"><a class=pager__link href=../../../posts/dailyreports/2025-11-17/ rel=next><span class=pager__subtitle>Next&#8201;Â»</span><p class=pager__title>ç§‘ç ”æ—¥æŠ¥ 2025-11-17</p></a></div></nav><section class=comments><div id=disqus_thread></div><script>window.disqus_config=function(){},function(){if(["localhost","127.0.0.1"].indexOf(window.location.hostname)!=-1){document.getElementById("disqus_thread").innerHTML="Disqus comments not available by default when the website is previewed locally.";return}var t=document,e=t.createElement("script");e.async=!0,e.src="//kkitown.disqus.com/embed.js",e.setAttribute("data-timestamp",+new Date),(t.head||t.body).appendChild(e)}()</script><noscript>Please enable JavaScript to view the <a href=https://disqus.com/?ref_noscript>comments powered by Disqus.</a></noscript><a href=https://disqus.com class=dsq-brlink>comments powered by <span class=logo-disqus>Disqus</span></a></section></div><aside class=sidebar><div class="widget-search widget"><form class=widget-search__form role=search method=get action=https://google.com/search><input class=widget-search__field type=search placeholder=Searchâ€¦ name=q aria-label=Searchâ€¦>
<input class=widget-search__submit type=submit value=Search>
<input type=hidden name=sitesearch value=https://ixxmu.github.io/></form></div><div class="widget-recent widget"><h4 class=widget__title>Recent Posts</h4><div class=widget__content><ul class=widget__list><li class=widget__item><a class=widget__link href=../../../posts/dailyreports/2026-01-10/>ç§‘ç ”æ—¥æŠ¥ 2026-01-10</a></li><li class=widget__item><a class=widget__link href=../../../posts/dailyreports/2026-01-09/>ç§‘ç ”æ—¥æŠ¥ 2026-01-09</a></li><li class=widget__item><a class=widget__link href=../../../posts/dailyreports/2026-01-08/>ç§‘ç ”æ—¥æŠ¥ 2026-01-08</a></li><li class=widget__item><a class=widget__link href=../../../posts/dailyreports/2026-01-07/>ç§‘ç ”æ—¥æŠ¥ 2026-01-07</a></li><li class=widget__item><a class=widget__link href=../../../posts/dailyreports/2026-01-06/>ç§‘ç ”æ—¥æŠ¥ 2026-01-06</a></li></ul></div></div><div class="widget-categories widget"><h4 class=widget__title>Categories</h4><div class=widget__content><ul class=widget__list><li class=widget__item><a class=widget__link href=../../../categories/dailyreport/>DailyReport</a></li><li class=widget__item><a class=widget__link href=../../../categories/learnr/>LearnR</a></li></ul></div></div><div class="widget-taglist widget"><h4 class=widget__title>Tags</h4><div class=widget__content><a class="widget-taglist__link widget__link btn" href=../../../tags/daily/ title=Daily>Daily (73)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/research/ title=Research>Research (73)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week022026/ title=Week022026>Week022026 (5)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week452025/ title=Week452025>Week452025 (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week462025/ title=Week462025>Week462025 (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week472025/ title=Week472025>Week472025 (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week482025/ title=Week482025>Week482025 (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week492025/ title=Week492025>Week492025 (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week502025/ title=Week502025>Week502025 (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week512025/ title=Week512025>Week512025 (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week522025/ title=Week522025>Week522025 (7)</a></div><a href=../../../tags/></a></div><div class="widget-social widget"><h4 class="widget-social__title widget__title">Social</h4><div class="widget-social__content widget__content"><div class="widget-social__item widget__item"><a class="widget-social__link widget__link btn" title=Facebook rel="noopener noreferrer" href=https://facebook.com/username target=_blank><svg class="widget-social__link-icon icon icon-facebook" width="24" height="24" viewBox="0 0 352 352"><path d="m0 32v288c0 17.5 14.5 32 32 32h288c17.5.0 32-14.5 32-32V32c0-17.5-14.5-32-32-32H32C14.5.0.0 14.5.0 32zm320 0v288h-83V212h41.5l6-48H237v-31c0-14 3.5-23.5 23.5-23.5h26V66c-4.4-.6-19.8-1.5-37.5-1.5-36.9.0-62 22.2-62 63.5v36h-42v48h42v108H32V32z"/></svg>
<span>Facebook</span></a></div><div class="widget-social__item widget__item"><a class="widget-social__link widget__link btn" title=Twitter rel="noopener noreferrer" href=https://twitter.com/username target=_blank><svg class="widget-social__link-icon icon icon-twitter" width="24" height="24" viewBox="0 0 384 312"><path d="m384 36.9c-14.1 6.3-29.3 10.5-45.2 12.4 16.3-9.7 28.8-25.2 34.6-43.6-15.2 9-32.1 15.6-50 19.1-14.4-15.2-34.9-24.8-57.5-24.8-43.5.0-78.8 35.3-78.8 78.8.0 6.2.7 12.2 2 17.9-65.5-3.3-123.5-34.6-162.4-82.3C20 26 16.1 39.6 16.1 54c0 27.3 13.9 51.4 35 65.6-12.9-.4-25.1-4-35.7-9.9v1c0 38.2 27.2 70 63.2 77.2-6.6 1.8-13.6 2.8-20.8 2.8-5.1.0-10-.5-14.8-1.4 10 31.3 39.1 54.1 73.6 54.7-27 21.1-60.9 33.7-97.8 33.7-6.4.0-12.6-.4-18.8-1.1C34.9 299 76.3 312 120.8 312c144.9.0 224.1-120 224.1-224.1.0-3.4-.1-6.8-.2-10.2 15.4-11.1 28.7-25 39.3-40.8z"/></svg>
<span>Twitter</span></a></div><div class="widget-social__item widget__item"><a class="widget-social__link widget__link btn" title=Instagram rel="noopener noreferrer" href=https://www.instagram.com/username target=_blank><svg class="widget-social__link-icon icon icon-instagram" width="24" height="24" viewBox="0 0 256 256"><circle cx="193" cy="59" r="15"/><path fill-rule="evenodd" d="M101 0h54c41 0 58.4 3.9 74.5 17C256.2 37.5 256 74.8 256 97.7v60c0 26.7.0 60.4-26.5 81.4-16 13.4-33.5 16.9-74.5 16.9h-54c-41 0-57.5-3.5-74.5-16.9C1 218.9.5 186.3.1 160.5L0 155V97.7c0-23-.2-60.2 26.5-80.7C45 2 60 0 101 0zm4.9 23h44.3c45.8.0 58.3 3.5 70.3 17.5 11.8 13.2 12 30.1 12.5 62.9V156c.2 20.8.3 45.8-12.5 59.5-12 14-24.5 17.5-70.3 17.5h-44.3c-45.9.0-57.3-3.5-70.4-17.5-12.2-13-12.3-36.5-12.4-56.7v-55.6c.4-32.6.7-49.6 12.4-62.7C48 26.5 60 23 105.9 23zm19.6 144.5a42 42 0 100-84 42 42 0 000 84zm0 22.5a64.5 64.5.0 100-129 64.5 64.5.0 000 129z"/></svg>
<span>Instagram</span></a></div></div></div></aside></div><footer class=footer><div class="container footer__container flex"><div class=footer__copyright>&copy; 2026 ç”Ÿä¿¡æ™®æ‹‰æ–¯.
<span class=footer__copyright-credits>Generated with <a href=https://gohugo.io/ rel="nofollow noopener" target=_blank>Hugo</a> and <a href=https://github.com/Vimux/Mainroad/ rel="nofollow noopener" target=_blank>Mainroad</a> theme.</span></div></div></footer></div><script async defer src=../../../js/menu.js></script><script src=../../../js/custom.js></script><script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.6/MathJax.js?config=TeX-AMS-MML_HTMLorMML" async></script></body></html>